Evidence mapPaperPMID 42450128Full record

ReviewInternational journal of molecular sciences2026

Neuroinflammation in Epilepsy: Biochemical and Molecular Mechanisms and Implications for Natural Product-Driven Drug Discovery.

Arthur Lins Dias, Pablo R da Silva, Livia R P Souza, Hugo F O Pires, Maria C F Gonçalves, Luiza C D Neri, Nayana M M V Barbosa, André Luiz Leocádio de Souza Matos, Anuraj Nayarisseri, Marcus T Scotti and 4 more

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Arthur Lins DiasInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0003-4278-7596
Pablo R da SilvaInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0001-8354-3198
Livia R P SouzaInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Hugo F O PiresInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Maria C F GonçalvesInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Luiza C D NeriInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Nayana M M V BarbosaInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0009-0008-4822-4616
André Luiz Leocádio de Souza MatosInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Anuraj NayarisseriIn Silico Research Laboratory, Eminent Biosciences, Indore 452010, India.ORCID 0000-0003-2567-9630
Marcus T ScottiPostgraduate Program in Natural and Synthetic Bioactive Compounds, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0003-4863-8057
Adriana M F de Oliveira-GolzioInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Cícero F B FelipeInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.
Mirian Graciela da Silva Stiebbe SalvadoriInstitute of Drugs and Medicines Research, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0002-4674-7922
Luciana ScottiPostgraduate Program in Natural and Synthetic Bioactive Compounds, Federal University of Paraíba, João Pessoa 58051-900, Brazil.ORCID 0000-0003-1866-4107

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epilepsy is a chronic neurological disorder prevalent worldwide, characterized by recurrent episodes of epileptic seizures. The primary current treatment approach is pharmacological, aimed at reducing the intensity and frequency of seizures, though it does not provide a cure. Neuroinflammation plays a central role in epilepsy by activating glial cells and stimulating the release of inflammatory mediators, further disrupting the balance between excitation and inhibition, thereby promoting the onset and recurrence of seizures. Furthermore, persistent inflammatory processes induce synaptic remodeling and the formation of dysfunctional neural circuits, establishing a pathological cycle in which inflammation and epileptic activity feed into each other. In this regard, natural products represent an important avenue for the discovery of new treatments. Thus, this review aimed to relate the role of the main inflammatory targets (Inflammasome/NLRP3, NF-κB, MAPK, mTOR, COX-2/PGE2, and TLR4/HMGB1) to epilepsy and to investigate in the literature natural products acting through these pathways in the treatment of epileptic seizures. Consequently, inflammatory pathways have emerged as critical targets in epilepsy, highlighting the importance of strategies capable of modulating neuroinflammatory processes. In this context, natural products stand out as promising therapeutic alternatives, given their multitarget mechanisms of action, potential to attenuate neuroinflammation and neuronal hyperexcitability.

Indexed as

Biological ProductsDrug DiscoveryEpilepsyNeuroinflammatory DiseasesAnimalsAnticonvulsantsHumansInflammationSignal TransductionAnticonvulsantsBiological Productsdrug discoveryepilepsynatural productsneuroinflammation

Identifiers

PMID42450128
PMCPMC13362060

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.